TW200738285A - Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility - Google Patents

Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility

Info

Publication number
TW200738285A
TW200738285A TW095128584A TW95128584A TW200738285A TW 200738285 A TW200738285 A TW 200738285A TW 095128584 A TW095128584 A TW 095128584A TW 95128584 A TW95128584 A TW 95128584A TW 200738285 A TW200738285 A TW 200738285A
Authority
TW
Taiwan
Prior art keywords
sustained
strong
active ingredient
ingredient release
pharmaceutical form
Prior art date
Application number
TW095128584A
Other languages
English (en)
Inventor
Claudia Guthmann
Heiko Kranz
Ralph Lipp
Torsten Wagner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of TW200738285A publication Critical patent/TW200738285A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095128584A 2005-08-05 2006-08-04 Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility TW200738285A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05090228A EP1749519A1 (de) 2005-08-05 2005-08-05 Arzneiform mit Retardtierter pH-unabhängiger Wirkstofffreisetzung für Wirkstoffe mit starker pH-abhängiger Löslichkeit

Publications (1)

Publication Number Publication Date
TW200738285A true TW200738285A (en) 2007-10-16

Family

ID=35448205

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095128584A TW200738285A (en) 2005-08-05 2006-08-04 Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility

Country Status (11)

Country Link
EP (2) EP1749519A1 (zh)
JP (1) JP2009503011A (zh)
CN (1) CN101257895A (zh)
AR (1) AR055110A1 (zh)
CA (1) CA2617280A1 (zh)
DO (1) DOP2006000184A (zh)
GT (1) GT200600353A (zh)
PE (1) PE20070464A1 (zh)
TW (1) TW200738285A (zh)
UY (1) UY29728A1 (zh)
WO (1) WO2007017219A2 (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2612989A1 (en) * 2006-05-08 2007-11-08 Mcneil-Ppc, Inc. Osmotic dosage form
JP5228359B2 (ja) * 2007-04-12 2013-07-03 ニプロ株式会社 主薬粒子及びその製造方法ならびに口腔内崩壊錠
US20130189377A1 (en) * 2010-07-27 2013-07-25 Norgine Bv Compositions
CN103093211B (zh) * 2013-01-27 2015-09-30 西安电子科技大学 基于深度核信息图像特征的人体运动跟踪方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4627851A (en) * 1984-10-26 1986-12-09 Alza Corporation Colonic-therapeutic delivery system
SE460945B (sv) * 1987-01-15 1989-12-11 Lejus Medical Ab En multipel-unit-dos komposition av furosemid
CN1096862C (zh) * 1994-05-06 2002-12-25 辉瑞大药厂 阿齐霉素的控释剂型
US6207665B1 (en) 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents
AU2001246861A1 (en) * 2000-04-10 2001-10-23 Sumitomo Pharmaceuticals Co. Ltd. Sustained release preparations
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
DE10211289A1 (de) * 2002-03-14 2003-09-25 Basf Ag Kombination von Polyvinylacetat von wasserunlöslichen, säureunlöslichen oder alkaliunlöslichen Polymeren zur Hestellung von Filmüberzügen mit sehr kontrollierter Freisetzung und hoher Stabilität

Also Published As

Publication number Publication date
CA2617280A1 (en) 2007-02-15
UY29728A1 (es) 2007-02-28
WO2007017219A3 (en) 2007-06-28
GT200600353A (es) 2007-03-14
EP1926482A2 (en) 2008-06-04
AR055110A1 (es) 2007-08-08
PE20070464A1 (es) 2007-06-07
WO2007017219A2 (en) 2007-02-15
CN101257895A (zh) 2008-09-03
DOP2006000184A (es) 2007-05-31
JP2009503011A (ja) 2009-01-29
EP1749519A1 (de) 2007-02-07

Similar Documents

Publication Publication Date Title
WO2007008752A3 (en) Sustained release pharmaceutical compositions for highly water soluble drugs
WO2007036952A3 (en) Novel sustained release dosage form
NZ602968A (en) Extended release formulation containing a wax
WO2008109462A3 (en) Sustained release pellets comprising wax-like material
DK1792927T3 (da) Ny blokcopolymer, micelletilberedning og anticancermiddel indeholdende samme som aktiv ingrediens
RS20080439A (en) Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer
WO2006009987A3 (en) Dissolvable film composition
ECSP088560A (es) Formulacion de liberacion sostenida que comprende octreotida y dos o mas polimeros de polilactido-co-glicolido
BR0112311A (pt) Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso
WO2006124047A3 (en) Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2007056205A3 (en) Carboxyalkylcellulose esters for administration of poorly soluble pharmaceutically active agents
AU2003274681A1 (en) Dosage form comprising high dose high soluble active ingredient as modified release and low dose active ingredient as immediate release
MY145111A (en) Liquid formulations
WO2006069236A3 (en) Sustained release tooth whitening formulations and systems
MY151468A (en) Controlled release solid preparation
WO2003035051A3 (en) The use of proton sequestering agents in drug formulations
WO2007014124A3 (en) High drug load formulations and dosage forms
WO2006123364A3 (en) Oral drug delivery system providing a coating comprising both a cellulose and a methacrylic acid derivative
WO2008060934A8 (en) Formulations of tetrahydropyridine antiplatelet agents for parenteral or oral administration
BG108516A (en) Pharmaceutical formulation
CY1107819T1 (el) Φαρμακευτικη διαμορφωση της ολανζαπινης
WO2007017331A3 (en) Immediate release therapeutic systems for improved oral absorption of 7- [ (e) -tert-butyloxyiminomethyl] camptothecin
TW200738285A (en) Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
MX2007013327A (es) Formulaciones de liberacion prolongada.
WO2006034147A3 (en) Compositions and methods for the preparation and administration of poorly water soluble drugs